Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $178.5 which represents a decrease of $-1.03 or -0.57% from the prior close of $179.53. The stock opened at $179.2 and touched a low of $176.18 ...

U.S. equities slumped at midday after the December jobs report came in higher than anticipated, putting more Federal Reserve rate cuts in doubt.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

Investment analysts at Leerink Partnrs dropped their FY2024 EPS estimates for AbbVie in a research note issued to investors ...

The stock market saw something incredible in 2024, with the “Magnificent 7” tech giants leading the charge and driving a huge ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 6. Analyst David Risinger ...

Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for AbbVie in a research report issued on Monday, January ...

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $179.53 which represents a decrease of $-0.57 or -0.32% from the prior close of $180.1. The stock opened at $179.63 and touched a low of ...